CN1066147C - 嘌呤衍生物及其制备方法 - Google Patents

嘌呤衍生物及其制备方法 Download PDF

Info

Publication number
CN1066147C
CN1066147C CN96198457.0A CN96198457A CN1066147C CN 1066147 C CN1066147 C CN 1066147C CN 96198457 A CN96198457 A CN 96198457A CN 1066147 C CN1066147 C CN 1066147C
Authority
CN
China
Prior art keywords
amino
carbamoyl
phenyl
ethyl
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN96198457.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN1202896A (zh
Inventor
J·齐默曼
H－G·凯普拉洛
P·伊姆巴克
P·福里特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN1202896A publication Critical patent/CN1202896A/zh
Application granted granted Critical
Publication of CN1066147C publication Critical patent/CN1066147C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN96198457.0A 1995-11-01 1996-10-22 嘌呤衍生物及其制备方法 Expired - Fee Related CN1066147C (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CH3094/1995 1995-11-01
CH309495 1995-11-01
CH3094/95 1995-11-01
CH2213/96 1996-09-10
CH221396 1996-09-10
CH2213/1996 1996-09-10
PCT/EP1996/004573 WO1997016452A1 (en) 1995-11-01 1996-10-22 Purine derivatives and processes for their preparation

Publications (2)

Publication Number Publication Date
CN1202896A CN1202896A (zh) 1998-12-23
CN1066147C true CN1066147C (zh) 2001-05-23

Family

ID=25689809

Family Applications (1)

Application Number Title Priority Date Filing Date
CN96198457.0A Expired - Fee Related CN1066147C (zh) 1995-11-01 1996-10-22 嘌呤衍生物及其制备方法

Country Status (13)

Country Link
US (1) US7091346B1 (enExample)
EP (1) EP0874846B1 (enExample)
JP (2) JP4004066B2 (enExample)
CN (1) CN1066147C (enExample)
AR (1) AR004134A1 (enExample)
AT (1) ATE236161T1 (enExample)
AU (1) AU7296896A (enExample)
BR (1) BR9611157A (enExample)
CA (1) CA2234609C (enExample)
DE (1) DE69627195T2 (enExample)
ES (1) ES2196181T3 (enExample)
PT (1) PT874846E (enExample)
WO (1) WO1997016452A1 (enExample)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2741881B1 (fr) 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
US6794390B2 (en) * 1996-08-02 2004-09-21 Cv Therapeutics, Inc. Purine inhibitors of cyclin dependent kinase 2 & ikappabalpha
US5866702A (en) * 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
US6790958B2 (en) * 1996-08-02 2004-09-14 Robert T. Lum Purine inhibitors of cyclin dependent kinase 2 & IKBA
AU4920397A (en) * 1996-10-11 1998-05-11 Chiron Corporation Purine inhibitors of glycogen synthase kinase 3 (gsk3)
US6432947B1 (en) * 1997-02-19 2002-08-13 Berlex Laboratories, Inc. N-heterocyclic derivatives as NOS inhibitors
JP2001516694A (ja) 1997-08-07 2001-10-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア プロテインキナーゼ、ｇプロテイン及びポリメラーゼのプリン阻害剤
US6573044B1 (en) 1997-08-07 2003-06-03 The Regents Of The University Of California Methods of using chemical libraries to search for new kinase inhibitors
CA2306082A1 (en) 1997-10-27 1999-05-06 Agouron Pharmaceuticals, Inc. Substituted 4-amino-thiazol-2-y compounds as cdks inhibitors
WO1999031072A1 (en) * 1997-12-18 1999-06-24 E.I. Du Pont De Nemours And Company Cyclohexylamine arthropodicides and fungicides
TR200002482T2 (tr) * 1998-02-26 2002-10-21 Aventis Pharmaceuticals Inc. 6,9-Diikameli 2-(Trans-(4-Aminosiklohekzil) Amino)Pürinler
US6642231B2 (en) * 1998-02-26 2003-11-04 Aventis Pharmaceuticals Inc. 6,9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
US6479487B1 (en) * 1998-02-26 2002-11-12 Aventis Pharmaceuticals Inc. 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
RU2200162C2 (ru) * 1998-02-26 2003-03-10 Авентис Фармасьютикалз Инк. 6,9-дизамещенные 2-[транс(4-аминоциклогексил)амино] пурины
US6413974B1 (en) * 1998-02-26 2002-07-02 Aventis Pharmaceuticals Inc. 6,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines
CZ27399A3 (cs) * 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
GB9903762D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
FR2793794B1 (fr) * 1999-05-21 2001-07-27 Hoechst Marion Roussel Inc Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
GB9918035D0 (en) * 1999-07-30 1999-09-29 Novartis Ag Organic compounds
EP1244668B1 (en) * 2000-01-07 2006-04-05 Universitaire Instelling Antwerpen Purine derivatives, process for their preparation and use thereof
WO2001082967A1 (fr) * 2000-04-28 2001-11-08 Yamanouchi Pharmaceutical Co., Ltd. Compositions medicinales destinees a supprimer la production de ?-amyloide
US6861524B2 (en) 2000-10-31 2005-03-01 Aventis Pharmaceuticals Inc. Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents
FR2818642B1 (fr) * 2000-12-26 2005-07-15 Hoechst Marion Roussel Inc Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilistion
PE20030008A1 (es) 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
DE60205376T2 (de) 2001-06-27 2006-04-06 Cyclacel Ltd. 2,6,9-substituierte purinderivate und ihre verwendung bei der behandlung proliferativer krankheiten
CZ294535B6 (cs) * 2001-08-02 2005-01-12 Ústav Experimentální Botaniky Avčr Heterocyklické sloučeniny na bázi N6-substituovaného adeninu, způsoby jejich přípravy, jejich použití pro přípravu léčiv, kosmetických přípravků a růstových regulátorů, farmaceutické přípravky, kosmetické přípravky a růstové regulátory tyto sloučeniny obsahující
US20040248906A1 (en) 2001-08-10 2004-12-09 Donato Nicholas J Use of c-src inhibitors alone or in combination with st1571 for the treatment of leukaemia
AU2002342051B2 (en) * 2001-10-12 2009-06-11 Irm Llc Kinase inhibitor scaffolds and methods for their preparation
GB0219052D0 (en) 2002-08-15 2002-09-25 Cyclacel Ltd New puring derivatives
GB0219054D0 (en) 2002-08-15 2002-09-25 Cyclacel Ltd New purine derivatives
CA2499593C (en) 2002-09-19 2011-08-16 Michael P. Dwyer Pyrazolopyridines as cyclin dependent kinase inhibitors
US7273864B2 (en) * 2002-10-15 2007-09-25 The Scripps Research Institute Compositions and methods for inducing osteogenesis
EP1608631A4 (en) 2003-03-28 2008-08-20 Scios Inc BICYCLIC PYRIMIDININHIBITORS OF TGF BETA
US20050288290A1 (en) * 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
US7439246B2 (en) 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
WO2007070872A1 (en) * 2005-12-15 2007-06-21 Rigel Pharmaceuticals, Inc. Kinase inhibitors and their uses
RS53588B1 (sr) 2006-12-08 2015-02-27 Irm Llc Jedinjenja i kompozicije kao inhibitori protein kinaza
BRPI0720264B1 (pt) * 2006-12-08 2022-03-03 Novartis Ag Compostos e composições como inibidores de proteína cinase
JP5703432B2 (ja) * 2007-03-28 2015-04-22 ノイロサーチ アクティーゼルスカブ プリニル誘導体及びカリウムチャネルモジュレーターとしてのそれらの使用
EP2142545A1 (en) 2007-03-28 2010-01-13 NeuroSearch A/S Purinyl derivatives and their use as potassium channel modulators
CZ302225B6 (cs) * 2007-07-04 2010-12-29 Univerzita Palackého v Olomouci Substituované 6-anilinopurinové deriváty jako inhibitory cytokinin oxidasy a prípravky obsahující tyto slouceniny
CA2720946C (en) * 2008-04-07 2013-05-28 Irm Llc Compounds and compositions as protein kinase inhibitors
EP2344501A1 (en) * 2008-09-26 2011-07-20 NeuroSearch A/S Substituted purinyl-pyrazol derivatives and their use as potassium channel modulators
US8268838B2 (en) 2008-09-26 2012-09-18 Neurosearch A/S Substituted purinyl-pyrazole derivatives and their use as potassium channel modulators
MX2013010330A (es) 2011-03-09 2014-11-26 Richard G Pestell Líneas de célula cancerosa de próstata, signaturas de gen, y usos de las mismas.
WO2013074986A1 (en) 2011-11-17 2013-05-23 Dana-Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
HK1209673A1 (en) 2012-05-14 2016-04-08 Prostagene Llc Using modulators of ccr5 for treating cancer
JP6223443B2 (ja) 2012-06-26 2017-11-01 サニオナ・エイピイエス フェニルトリアゾール誘導体及びｇａｂａａ受容体複合体を調節するための該フェニルトリアゾール誘導体の使用
KR101652010B1 (ko) * 2013-03-27 2016-08-29 재단법인 아산사회복지재단 p34의 발현 억제제 또는 활성 억제제를 유효성분으로 포함하는 암의 치료 또는 전이 억제용 조성물
JP6491202B2 (ja) 2013-10-18 2019-03-27 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド サイクリン依存性キナーゼ７（ｃｄｋ７）の多環阻害剤
EP3194572B1 (en) 2014-07-30 2023-10-25 Yeda Research and Development Co. Ltd. Media for culturing pluripotent stem cells
EP3236959B1 (en) 2014-12-23 2025-09-24 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
CA2978518C (en) * 2015-03-27 2023-11-21 Nathanael S. Gray Inhibitors of cyclin-dependent kinases
JP7028766B2 (ja) 2015-09-09 2022-03-02 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼの阻害剤
US10722515B2 (en) 2016-09-30 2020-07-28 Sri International Dual CLK/CDK1 inhibitors for cancer treatment
WO2020005807A1 (en) 2018-06-25 2020-01-02 Dana-Farber Cancer Institute, Inc. Taire family kinase inhibitors and uses thereof
EP3914698B1 (en) 2019-01-23 2024-12-11 Yeda Research and Development Co. Ltd Culture media for pluripotent stem cells
CN120289460A (zh) * 2024-01-09 2025-07-11 中国科学院合肥物质科学研究院 含有嘌呤环的化合物及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0212535A1 (de) * 1985-08-17 1987-03-04 Roche Diagnostics GmbH N6-Disubstituierte Purinderivate, Verfahren zu deren Herstellung sowie diese Verbindungen enthaltende Arzneimittel

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU626983B2 (en) 1989-01-31 1992-08-13 Whitby Research, Inc. N6-substituted 9-methyladenines
ES2130246T3 (es) * 1992-01-06 1999-07-01 Wellcome Found Nucleosidos terapeuticos de la serie 2',3'-didesoxi-3'-fluoro-purina.
US6403599B1 (en) 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
FR2741881B1 (fr) 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
US6107300A (en) 1996-03-27 2000-08-22 Dupont Pharmaceuticals Arylamino fused pyrimidines
US5866702A (en) 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
US5753635A (en) 1996-08-16 1998-05-19 Berlex Laboratories, Inc. Purine derivatives and their use as anti-coagulants
AU4920397A (en) 1996-10-11 1998-05-11 Chiron Corporation Purine inhibitors of glycogen synthase kinase 3 (gsk3)
GB9903762D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds
AU2002342051B2 (en) * 2001-10-12 2009-06-11 Irm Llc Kinase inhibitor scaffolds and methods for their preparation
US7273864B2 (en) * 2002-10-15 2007-09-25 The Scripps Research Institute Compositions and methods for inducing osteogenesis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0212535A1 (de) * 1985-08-17 1987-03-04 Roche Diagnostics GmbH N6-Disubstituierte Purinderivate, Verfahren zu deren Herstellung sowie diese Verbindungen enthaltende Arzneimittel

Also Published As

Publication number Publication date
AR004134A1 (es) 1998-09-30
DE69627195D1 (de) 2003-05-08
AU7296896A (en) 1997-05-22
PT874846E (pt) 2003-08-29
CN1202896A (zh) 1998-12-23
ATE236161T1 (de) 2003-04-15
WO1997016452A1 (en) 1997-05-09
JP2007231023A (ja) 2007-09-13
EP0874846B1 (en) 2003-04-02
ES2196181T3 (es) 2003-12-16
BR9611157A (pt) 1999-03-30
HK1016580A1 (en) 1999-11-05
JP4004066B2 (ja) 2007-11-07
EP0874846A1 (en) 1998-11-04
US7091346B1 (en) 2006-08-15
CA2234609A1 (en) 1997-05-09
JPH11514336A (ja) 1999-12-07
DE69627195T2 (de) 2004-01-29
CA2234609C (en) 2006-11-28

Similar Documents

Publication Publication Date Title
CN1066147C (zh) 嘌呤衍生物及其制备方法
CN1047776C (zh) 具有药理学活性的吡啶类衍生物及其制备方法
US6083953A (en) 2- (2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3- propanediol derivative
TW434242B (en) 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative
JP2000516626A (ja) 置換ピロロピリミジンおよびその製造方法
JP2002537300A5 (enExample)
EP1789045A2 (en) Chemical compounds
US5543414A (en) Achiral amino acid acyl esters of ganciclovir and its derivatives
JP2004043429A (ja) 新規キサンチン誘導体およびｄｐｐｉｖ阻害剤
JP2010507581A (ja) ＰＫＣ−θ阻害薬としてのプリン類
WO2008143674A1 (en) Purinones and 1h-imidazopyridinones as pkc-theta inhibitors
CN113717245B (zh) 含有2,8,9-三取代-9h-嘌呤结构片段的egfr降解剂及其盐和应用
WO2010102212A2 (en) Neurotrophin mimetics and uses thereof
WO1997023482A1 (en) 2,7-substituted octahydro-pyrrolo[1,2-a]pyrazine derivatives
CN1067885A (zh) 2-氨基嘧啶-4-甲酰胺衍生物及其制法和医疗应用
JPH10501526A (ja) 多薬物耐性に対する作用物質としてのカルバゾール誘導体
JPH10501527A (ja) 多重薬剤耐性細胞を抗腫瘍剤に対して感受性にするためのインドロカルバゾール誘導体
JPH10500394A (ja) 多重薬剤耐性細胞を抗腫瘍剤に対して感受性にするための多環式ラクタム誘導体
HK1016580B (en) Purine derivatives and processes for their preparation
JPH0834789A (ja) ピロロインドールカルボン酸エステル誘導体及びその製造方法
JPH0834788A (ja) ピロロベンゾカルバゾール誘導体及びその製造方法
JPH0834786A (ja) トリフルオロメチルピロロインドール誘導体及びその製造方法
JPH0834787A (ja) ピロロカルバゾール誘導体及びその製造方法
HK1012339B (en) 2-(2-amino-1, 6-dihydro-6-oxo-purin-9-yl)methoxy-1, 3-propanediol derivatives

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20010523

Termination date: 20091123